Pyrazole ligands: Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists

S. R. Stauffer, C. J. Coletta, R. Tedesco, G. Nishiguchi, K. Carlson, J. Sun, Benita S Katzenellenbogen, J. A. Katzenellenbogen

Research output: Contribution to journalArticle

Abstract

We have found that certain tetrasubstituted pyrazoles are high-affinity ligands for the estrogen receptor (ER) (Fink et al. Chem. Biol. 1999, 6, 205-219) and that one pyrazole is considerably more potent as an agonist on the ERα than on the ERβ subtype (Sun et al. Endocrinology 1999, 140, 800-804). To investigate what substituent pattern provides optimal ER binding affinity and the greatest enhancement of potency as an ERα-selective agonist, we prepared a number of tetrasubstituted pyrazole analogues with defined variations at certain substituent positions. Analysis of their binding affinity pattern shows that a C(4)-propyl substituent is optimal and that a p-hydroxyl group on the N(1)-phenyl group also enhances affinity and selectivity for ERα. The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERα with high affinity (ca. 50% that of estradiol), and it has a 410-fold binding affinity preference for ERα. It also activates gene transcription only through ERα. Thus, this compound represents the first ERα-specific agonist. We investigated the molecular basis for the exceptional ERα binding affinity and potency selectivity of pyrazole 4g by a further study of structure-affinity relationships in this series and by molecular modeling. These investigations suggest that the pyrazole triols prefer to bind to ERα with their C(3)-phenol in the estradiol A-ring binding pocket and that binding selectivity results from differences in the interaction of the pyrazole core and C(4)-propyl group with portions of the receptor where ERα has a smaller residue than ERβ. These ER subtype-specific interactions and the ER subtype-selective ligands that can be derived from them should prove useful in defining those biological activities in estrogen target cells that can be selectively activated through ERα.

Original languageEnglish (US)
Pages (from-to)4934-4947
Number of pages14
JournalJournal of Medicinal Chemistry
Volume43
Issue number26
DOIs
StatePublished - Dec 28 2000

Fingerprint

Structure-Activity Relationship
Estrogen Receptors
Estrogens
Ligands
pyrazole
Estradiol
Pyrazoles
Endocrinology
Phenol
Hydroxyl Radical

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Stauffer, S. R., Coletta, C. J., Tedesco, R., Nishiguchi, G., Carlson, K., Sun, J., ... Katzenellenbogen, J. A. (2000). Pyrazole ligands: Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists. Journal of Medicinal Chemistry, 43(26), 4934-4947. https://doi.org/10.1021/jm000170m

Pyrazole ligands : Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists. / Stauffer, S. R.; Coletta, C. J.; Tedesco, R.; Nishiguchi, G.; Carlson, K.; Sun, J.; Katzenellenbogen, Benita S; Katzenellenbogen, J. A.

In: Journal of Medicinal Chemistry, Vol. 43, No. 26, 28.12.2000, p. 4934-4947.

Research output: Contribution to journalArticle

Stauffer, SR, Coletta, CJ, Tedesco, R, Nishiguchi, G, Carlson, K, Sun, J, Katzenellenbogen, BS & Katzenellenbogen, JA 2000, 'Pyrazole ligands: Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists', Journal of Medicinal Chemistry, vol. 43, no. 26, pp. 4934-4947. https://doi.org/10.1021/jm000170m
Stauffer, S. R. ; Coletta, C. J. ; Tedesco, R. ; Nishiguchi, G. ; Carlson, K. ; Sun, J. ; Katzenellenbogen, Benita S ; Katzenellenbogen, J. A. / Pyrazole ligands : Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists. In: Journal of Medicinal Chemistry. 2000 ; Vol. 43, No. 26. pp. 4934-4947.
@article{d3ca2e44a34d4a459c3c5ac4a692bf1e,
title = "Pyrazole ligands: Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists",
abstract = "We have found that certain tetrasubstituted pyrazoles are high-affinity ligands for the estrogen receptor (ER) (Fink et al. Chem. Biol. 1999, 6, 205-219) and that one pyrazole is considerably more potent as an agonist on the ERα than on the ERβ subtype (Sun et al. Endocrinology 1999, 140, 800-804). To investigate what substituent pattern provides optimal ER binding affinity and the greatest enhancement of potency as an ERα-selective agonist, we prepared a number of tetrasubstituted pyrazole analogues with defined variations at certain substituent positions. Analysis of their binding affinity pattern shows that a C(4)-propyl substituent is optimal and that a p-hydroxyl group on the N(1)-phenyl group also enhances affinity and selectivity for ERα. The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERα with high affinity (ca. 50{\%} that of estradiol), and it has a 410-fold binding affinity preference for ERα. It also activates gene transcription only through ERα. Thus, this compound represents the first ERα-specific agonist. We investigated the molecular basis for the exceptional ERα binding affinity and potency selectivity of pyrazole 4g by a further study of structure-affinity relationships in this series and by molecular modeling. These investigations suggest that the pyrazole triols prefer to bind to ERα with their C(3)-phenol in the estradiol A-ring binding pocket and that binding selectivity results from differences in the interaction of the pyrazole core and C(4)-propyl group with portions of the receptor where ERα has a smaller residue than ERβ. These ER subtype-specific interactions and the ER subtype-selective ligands that can be derived from them should prove useful in defining those biological activities in estrogen target cells that can be selectively activated through ERα.",
author = "Stauffer, {S. R.} and Coletta, {C. J.} and R. Tedesco and G. Nishiguchi and K. Carlson and J. Sun and Katzenellenbogen, {Benita S} and Katzenellenbogen, {J. A.}",
year = "2000",
month = "12",
day = "28",
doi = "10.1021/jm000170m",
language = "English (US)",
volume = "43",
pages = "4934--4947",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "26",

}

TY - JOUR

T1 - Pyrazole ligands

T2 - Structure - Affinity/activity relationships and estrogen receptor-α-selective agonists

AU - Stauffer, S. R.

AU - Coletta, C. J.

AU - Tedesco, R.

AU - Nishiguchi, G.

AU - Carlson, K.

AU - Sun, J.

AU - Katzenellenbogen, Benita S

AU - Katzenellenbogen, J. A.

PY - 2000/12/28

Y1 - 2000/12/28

N2 - We have found that certain tetrasubstituted pyrazoles are high-affinity ligands for the estrogen receptor (ER) (Fink et al. Chem. Biol. 1999, 6, 205-219) and that one pyrazole is considerably more potent as an agonist on the ERα than on the ERβ subtype (Sun et al. Endocrinology 1999, 140, 800-804). To investigate what substituent pattern provides optimal ER binding affinity and the greatest enhancement of potency as an ERα-selective agonist, we prepared a number of tetrasubstituted pyrazole analogues with defined variations at certain substituent positions. Analysis of their binding affinity pattern shows that a C(4)-propyl substituent is optimal and that a p-hydroxyl group on the N(1)-phenyl group also enhances affinity and selectivity for ERα. The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERα with high affinity (ca. 50% that of estradiol), and it has a 410-fold binding affinity preference for ERα. It also activates gene transcription only through ERα. Thus, this compound represents the first ERα-specific agonist. We investigated the molecular basis for the exceptional ERα binding affinity and potency selectivity of pyrazole 4g by a further study of structure-affinity relationships in this series and by molecular modeling. These investigations suggest that the pyrazole triols prefer to bind to ERα with their C(3)-phenol in the estradiol A-ring binding pocket and that binding selectivity results from differences in the interaction of the pyrazole core and C(4)-propyl group with portions of the receptor where ERα has a smaller residue than ERβ. These ER subtype-specific interactions and the ER subtype-selective ligands that can be derived from them should prove useful in defining those biological activities in estrogen target cells that can be selectively activated through ERα.

AB - We have found that certain tetrasubstituted pyrazoles are high-affinity ligands for the estrogen receptor (ER) (Fink et al. Chem. Biol. 1999, 6, 205-219) and that one pyrazole is considerably more potent as an agonist on the ERα than on the ERβ subtype (Sun et al. Endocrinology 1999, 140, 800-804). To investigate what substituent pattern provides optimal ER binding affinity and the greatest enhancement of potency as an ERα-selective agonist, we prepared a number of tetrasubstituted pyrazole analogues with defined variations at certain substituent positions. Analysis of their binding affinity pattern shows that a C(4)-propyl substituent is optimal and that a p-hydroxyl group on the N(1)-phenyl group also enhances affinity and selectivity for ERα. The best compound in this series, a propylpyrazole triol (PPT, compound 4g), binds to ERα with high affinity (ca. 50% that of estradiol), and it has a 410-fold binding affinity preference for ERα. It also activates gene transcription only through ERα. Thus, this compound represents the first ERα-specific agonist. We investigated the molecular basis for the exceptional ERα binding affinity and potency selectivity of pyrazole 4g by a further study of structure-affinity relationships in this series and by molecular modeling. These investigations suggest that the pyrazole triols prefer to bind to ERα with their C(3)-phenol in the estradiol A-ring binding pocket and that binding selectivity results from differences in the interaction of the pyrazole core and C(4)-propyl group with portions of the receptor where ERα has a smaller residue than ERβ. These ER subtype-specific interactions and the ER subtype-selective ligands that can be derived from them should prove useful in defining those biological activities in estrogen target cells that can be selectively activated through ERα.

UR - http://www.scopus.com/inward/record.url?scp=0034727853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034727853&partnerID=8YFLogxK

U2 - 10.1021/jm000170m

DO - 10.1021/jm000170m

M3 - Article

C2 - 11150164

AN - SCOPUS:0034727853

VL - 43

SP - 4934

EP - 4947

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 26

ER -